A Boulder company that uses a particular kind of cow’s milk for health and medical products has nabbed another $52 million in financing.

PanTheryx began in 2007 with a patented technology that uses bovine colostrum, the milk produced by a cow during the first few days after the birth of a calf, to treat pediatric diarrhea.

Today, the company says it is the largest producer of that kind of milk, called bovine colostrum. The milk is naturally rich with antibodies that help protect newborns against disease, former PanTheryx CEO Mark Braman told the Denver Business Journal in 2019 following a prior $50 million raise.

Its unique properties also make bovine colostrum an ideal ingredient to help with early childhood nutrition, immune health, digestive health, animal health, sports nutrition and skin health, according to the company.

PanTheryx returned to the fundraising scene in October with a fresh $52 million reported via a Form D with the U.S. Securities and Exchange Commission.

Through a spokesperson, PanTheryx declined to share more about the raise or its plans for the future. However, the company states on its website that its current investment focus is on research and new technologies that will allow for the continued commercialization of colostrum products.

PanTheryx provides colostrum products to partners and makes three of its own consumer brands: its flagship product DiaResQ, a “natural alternative” for children and adults with diarrhea, a line of probiotics called TruBiotics, and a nutritional supplement called Life’s First Naturals.

According to PitchBook data, Florida-based TruBiotics was acquired by PanTheryx in 2021. The company also acquired Greenteaspoon in 2020.

In 2015, PanTheryx landed a distribution deal with India’s biggest pharmaceutical company to offer the product in several markets. Two years later, the company acquired two U.S. producers of bovine colostrum to become a vertically integrated operation.

Today, PanTheryx says it has a network of over 1,000 dairies that supply bovine colostrum.

Full article posted here.